Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.

about

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions

P2860

Q55331819-445A3AE1-78D7-432A-8F58-D0849F7C83DA Q58698705-F5C54837-9868-44EA-9626-F1ABD26FD895

P2860

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.

Item

http://www.wikidata.org/entity/Q47109527

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.

@en

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.

@nl

type

Item

label

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.

@en

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.

@nl

prefLabel

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.

@en

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.

@nl

P1476

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.

@en

P2093

Zoran Culig

http://www.w3.org/2001/XMLSchema#string

P2860

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

Overcoming mutation-based resistance to antiandrogens with rational drug design

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer

Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.

Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells

Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.

Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells.

Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model

Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer

Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer

P2888

s40610-017-0079-1

P304

230-235

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S40610-017-0079-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29214142

http://www.w3.org/2001/XMLSchema#string

P932

5700216

http://www.w3.org/2001/XMLSchema#string

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.

about

P2860

P2860

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P932